1. Home
  2. HBNC vs ABUS Comparison

HBNC vs ABUS Comparison

Compare HBNC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Horizon Bancorp Inc.

HBNC

Horizon Bancorp Inc.

N/A

Current Price

$20.74

Market Cap

962.4M

Sector

Finance

ML Signal

N/A

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

N/A

Current Price

$4.21

Market Cap

836.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HBNC
ABUS
Founded
1873
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
962.4M
836.0M
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
HBNC
ABUS
Price
$20.74
$4.21
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
★ $23.80
N/A
AVG Volume (30 Days)
610.6K
★ 3.7M
Earning Date
10-21-2026
11-12-2026
Dividend Yield
★ 3.05%
N/A
EPS Growth
N/A
★ 55.26
EPS
★ 1.00
0.84
Revenue
N/A
★ $14,083,000.00
Revenue This Year
$8.25
$1,208.75
Revenue Next Year
$5.44
N/A
P/E Ratio
$20.93
★ $5.07
Revenue Growth
N/A
★ 128.21
52 Week Low
$15.43
$3.50
52 Week High
$21.07
$5.45

Technical Indicators

Market Signals
Indicator
HBNC
ABUS
Relative Strength Index (RSI) 63.64 39.15
Support Level $19.13 $4.10
Resistance Level $21.04 $4.57
Average True Range (ATR) 0.43 0.13
MACD 0.16 0.03
Stochastic Oscillator 83.41 42.42

Price Performance

Historical Comparison
HBNC
ABUS

About HBNC Horizon Bancorp Inc.

Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: